期刊
CASE REPORTS IN ONCOLOGY
卷 14, 期 2, 页码 931-937出版社
KARGER
DOI: 10.1159/000515510
关键词
Metaplastic breast cancer; Exceptional response; Immunotherapy; Program death ligand-1
类别
资金
- Office of Human Research Services [P30CA072720]
- Rutgers Cancer Institute of New Jersey
Metaplastic breast cancer is a rare and aggressive subtype, often with poor prognosis and resistance to chemotherapy. Genomic profiling helps identify potential targeted therapies. Immunotherapy may be more effective for certain subtypes of MBC and requires further research.
Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. Resistance to chemotherapy often leads to local recurrence and distant metastasis. Genomic profiling has identified multiple molecular abnormalities that may translate to targetable therapies in MBC. These tumors are known to display higher PD-L1 expressivity than other subtypes of breast cancer, and disease control with pembrolizumab and chemotherapy has been documented. We identify a patient with metastatic, metaplastic TNBC, with mesenchymal components and osseous differentiation, who completed 2 years of pembrolizumab treatment and has remained without evidence of disease after 32 months of observation, while maintaining good quality of life. Future efforts should focus on immunotherapy response with respect to the various subtypes of MBC, and treatment should continue to be incorporated in clinical trials to maximize disease response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据